Abstract P5-14-05: The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study

• Published in: Cancer research (Chicago, Ill.) Vol. 80; no. 4_Supplement; pp. P5 - P5-14-05
• Main Authors: Lim, Elgene, Boyle, Frances, Okera, Meena, Loi, Sherene, Goksu, Sema Sezgin, van Hal, Gertjan, Hartman, Daisy G, Gable, Jonathon Colby, Price, Gregory L, Hossain, Anwar, Gainford, M C, Ezquerra, Meritxell Bellet
• Format: Journal Article
• Language: English
• Published: 15.02.2020

Abstract Background: Abemaciclib is an orally administered inhibitor of cyclin-dependent kinase (CDK) 4/6, dosed twice daily (BID) on a continuous schedule. Diarrhea is a frequently associated adverse event. It is predictable and manageable with antidiarrheal medication, typically occurs within the...